Trevi wraps up a $26M round to fund its anti-itching drug

New Haven, CT's Trevi Therapeutics banked another $11 million in venture cash, bringing its B round to $26 million and giving it the cash it needs to complete a pivotal trial for its top prospect. TPG Biotech led the round, which will get Nalbuphine ER, an oral extended-release opioid, through a currently enrolling Phase III trial. Trevi is recruiting 360 patients with uremic pruritus trial, a severe itching condition, and expects to post results in 2015. The company is also on track to start a Phase III trial in prurigo nodularis, another itching disorder, by year's end. More

Suggested Articles

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.

Grid Therapeutics is planning to start trials of its lead cancer immunotherapy GT103 next year after raising $5 million in second-round financing.

The IPO comes as the Flagship startup prepares to test its lead inflammatory disease and anticancer microbial strains in humans.